EDMONTON, ALBERTA--(CCNMatthews - April 27, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced it has received authorization from Health Canada to undertake a Phase I clinical trial for its lead ChimigenTM vaccine candidate, HepaVaxx B Vaccine, a potential treatment for chronic carriers of hepatitis B virus.
